Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medinol/Gore

This article was originally published in The Gray Sheet

Executive Summary

NIRTOP randomized study of 305 patients at 15 international centers demonstrates a 6.3% restenosis rate for lesions greater than 3 mm treated with the NirFlex bare metal coronary stent. The treatment arm showed late-loss rate of 0.65 mm in addition to target vessel revascularization rates of 4.4%, 7% and 8.9% at 180 days, 210 days and 280 days, respectively. Antonio Colombo, MD, San Raffaele Hospital, Milan, Italy, served as the study's principal investigator...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018469

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel